SK-PHARMA
Driven by Values
Powered by Technology
Latest news and
initiatives
Follow news and programs from SK-Pharma
Apocalyptic Generic Prophecy
Beyond the Pill
Pharmaceutical company, In the Line of Fire
Our Vision
SK-Pharma is a global pharmaceutical company committed to revolutionizing drug accessibility, mainly focusing on value-added medicines, precision medicine, orphan drugs, and complex generics. Our vision is anchored in integrating advanced technologies and data-driven methodologies to make informed business decisions, leading to enhanced healthcare solutions.
By adopting a patient-centric approach, we delve into understanding the patient journey in its entirety. This deep comprehension allows us to develop treatments that are not only effective but also customized to fit the unique lifestyles and needs of our patients.
We believe that managing a challenging health condition should not significantly disrupt the lives of patients or their caregivers. Upholding this belief, SK-Pharma employs the latest technological innovations to keep pace with emerging trends in drug development. Our commitment ensures that these advancements are seamlessly integrated into our product offerings, catering specifically to the needs and well-being of our patients.
Our vision is to create a healthcare environment where accessibility, personalization, and innovation converge, ultimately contributing to improved patient outcomes and quality of life.
Our Mission
SK-Pharma is dedicated to enhancing health and wellness by ensuring the broad accessibility of medicines to all patients in need. Our primary objective is to introduce complex generics and non-infringing medicines into strategic markets, including the MENA region & Israel, CIS, GCC, the Balkans, and Latin America. Moreover, our company is committed to providing vital access to pediatric and orphan drugs through a named patient program, catering to the needs of thousands globally.
Embracing our role as a data-driven company, we leverage advanced technologies for intelligent decision-making in product selection, launch strategies, and supply chain optimization. This approach is integral to our patient-centric mission, enabling us to develop and supply medications that are effective and tailored to individual patient needs and lifestyles.
Company Strategy
The strategy at SK-Pharma is built upon five key pillars that resonate with our core areas of interest:
- Elite business development
- Business intelligence
- IP & litigation expertise
- Data science
- Strategic regulatory affairs
These pillars underpin our ambition to be a market leader in value-added medicines and complex generics. We strive for our product launches to predominantly feature these categories, focusing on treatments that significantly enhance patient compliance and adherence.
Our strategy is centered on addressing unmet needs in the pharmaceutical industry, particularly in our specialized fields. We aim to create a stable yet innovative business environment where our advanced technological capabilities give us a competitive edge, fostering rapid growth and operational efficiency.
Meet our founders
Co-Founder
Ksenia is the Co-Founder and Managing Director of the SK-Pharma Group, a global pharmaceutical company with a presence in over 15 countries. SK-Pharma has launched its wide-ranging portfolio worldwide, mainly focusing on value-added medicines, precision medicine, orphan drugs, and complex generics. These products have been distributed to millions of patients globally.
Co-Founder
Dr. Shlomo is the Co-Founder and CEO of SK-Pharma Group, a global pharmaceutical company that manufactures, sells, and markets generic, specialty pharma, hybrid generics and biosimilar pharmaceutical products in over 15 countries.
Join our mission
We distribute pharmaceutical products to pharmacies, wholesalers, and manufacturers in over 40 geographic areas, such as the EU, GCC, MENA region, CIS, and LATAM. We acquire our medicines exclusively from selected qualified suppliers and
operate under strict compliance with GMP, GDP and specific regulatory bodies, such as the
Israel Ministry of Health. Contact us for more information.
Worldwide offices
Our company has representative offices in 7 countries as well as strategic partners
in more than 50 countries across the globe.
Our company’s growth is driven by branded products and global first-to-launch generics.
